Dramatic Responses in Cutaneous Sarcoidosis With JAK Inhibitor

(MedPage Today) -- NEW YORK CITY--Patients with longstanding sarcoidosis and skin involvement had dramatic improvement after 6 months of treatment with the Janus kinase (JAK) inhibitor tofacitinib (Xeljanz), a small open-label clinical series...